We are pleased that studies by Schwartzman et al confirm our initial case report describing the complete resolution of reflex sympathetic dystrophy (or CRPS) with thalidomide therapy.1 The patient we described is doing well and continues to receive thalidomide for the treatment of myeloma at a maintenance dose of 100 mg/d. With a current follow-up of 30 months, she remains asymptomatic and has no recurrence of CRPS. We fully concur with the plan by Schwartzman et al to initiate a multicenter, randomized trial to further define and establish the role of thalidomide for this serious and disabling condition.
Rajkumar SV, Fonseca R, Witzig TE. Thalidomide Has Activity in Treating Complex Regional Pain Syndrome—Reply. Arch Intern Med. 2003;163(12):1488. doi:10.1001/archinte.163.12.1487